Amicus Therapeutics (FOLD) : Sectoral Asset Management Inc reduced its stake in Amicus Therapeutics by 48.1% during the most recent quarter end. The investment management company now holds a total of 4,788,738 shares of Amicus Therapeutics which is valued at $33,233,842 after selling 4,437,407 shares in Amicus Therapeutics , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.Amicus Therapeutics makes up approximately 3.15% of Sectoral Asset Management Inc’s portfolio.
Other Hedge Funds, Including , Credit Suisse Ag boosted its stake in FOLD in the latest quarter, The investment management firm added 30,541 additional shares and now holds a total of 187,811 shares of Amicus Therapeutics which is valued at $1,303,408. Artal Group S.a. added FOLD to its portfolio by purchasing 1,250,000 company shares during the most recent quarter which is valued at $8,675,000. Amicus Therapeutics makes up approx 0.18% of Artal Group S.a.’s portfolio.Ubs Asset Management Americas Inc reduced its stake in FOLD by selling 550,060 shares or 92.44% in the most recent quarter. The Hedge Fund company now holds 45,000 shares of FOLD which is valued at $301,950.California State Teachers Retirement System boosted its stake in FOLD in the latest quarter, The investment management firm added 21,525 additional shares and now holds a total of 267,038 shares of Amicus Therapeutics which is valued at $1,813,188.
Amicus Therapeutics opened for trading at $7.01 and hit $7.1 on the upside on Monday, eventually ending the session at $7.01, with a gain of 0.43% or 0.03 points. The heightened volatility saw the trading volume jump to 17,81,029 shares. Company has a market cap of $996 M.
On the company’s financial health, Amicus Therapeutics reported $-0.40 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.36.Analysts expectations of $ .17.
Many Wall Street Analysts have commented on Amicus Therapeutics. BofA/Merrill Initiated Amicus Therapeutics on May 18, 2016 to “Buy”, Price Target of the shares are set at $10.
Amicus Therapeutics Inc. is a biopharmaceutical company. The Company focuses on the discovery development and commercialization of medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders (SDs). The Company’s lead product candidate is the pharmacological chaperone migalastat HCl (Galafold) a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Company’s development programs also include ERTs for LSDs including Fabry disease Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Company’s programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease SD-101 for Epidermolysis Bullosa (EB) as well as ERT products for Fabry disease Pompe disease and MPS I.